Dr. Fuster is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 W Arbor Dr
San Diego, CA 92103Phone+1 800-926-8273Fax+1 619-543-3183
Education & Training
- University of California (San Diego) Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1997 - 2000
- University of California (San Diego) Medical CenterResidency, Internal Medicine, 1993 - 1996
- David Geffen School of Medicine at UCLAClass of 1993
Certifications & Licensure
- CA State Medical License 1995 - 2026
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Early Diagnosis and Treatment of Sleep Disordered Breathing in Lung Cancer Start of enrollment: 2017 Nov 17
Publications & Presentations
PubMed
- Diversity of human salivary heparan sulfate.Charlotte B Spliid, Sanjay Mehta, Mark M Fuster, Cameron Martino, Claire L Morris
Glycobiology. 2024-12-10 - 1 citationsGlycocalyx transduces membrane leak in brain tumor cells exposed to sharp magnetic pulsing.Scott C Johns, Purva Gupta, Yi-Hung Lee, James Friend, Mark M Fuster
Biophysical Journal. 2023-11-21 - 3 citationsGenetic alteration of heparan sulfate in CD11c + immune cells inhibits inflammation and facilitates pathogen clearance during influenza A virus infection.So Young Kim, Purva Gupta, Scott C Johns, Elina I Zuniga, John R Teijaro
Scientific Reports. 2022-03-30
Grant Support
- Glycocalyx Targeting and Augmenting Cellular Immunity in Lung CancerVA SAN DIEGO HEALTHCARE SYSTEM2017–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: